BIO-RAD LABORATORIES-A (BIO) Fundamental Analysis & Valuation

NYSE:BIO • US0905722072

Current stock price

287.84 USD
+6.42 (+2.28%)
At close:
287.84 USD
0 (0%)
After Hours:

This BIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. BIO Profitability Analysis

1.1 Basic Checks

  • BIO had positive earnings in the past year.
  • In the past year BIO had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
  • BIO had a positive operating cash flow in each of the past 5 years.
BIO Yearly Net Income VS EBIT VS OCF VS FCFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • The Return On Assets of BIO (7.18%) is better than 87.50% of its industry peers.
  • BIO's Return On Equity of 10.20% is amongst the best of the industry. BIO outperforms 82.14% of its industry peers.
  • The Return On Invested Capital of BIO (2.02%) is better than 64.29% of its industry peers.
  • BIO had an Average Return On Invested Capital over the past 3 years of 2.32%. This is significantly below the industry average of 11.41%.
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROIC 2.02%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
BIO Yearly ROA, ROE, ROICBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20

1.3 Margins

  • The Profit Margin of BIO (29.42%) is better than 98.21% of its industry peers.
  • In the last couple of years the Profit Margin of BIO has declined.
  • BIO's Operating Margin of 10.30% is fine compared to the rest of the industry. BIO outperforms 71.43% of its industry peers.
  • BIO's Operating Margin has declined in the last couple of years.
  • BIO has a Gross Margin of 52.01%. This is in the better half of the industry: BIO outperforms 62.50% of its industry peers.
  • BIO's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
BIO Yearly Profit, Operating, Gross MarginsBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. BIO Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
  • The number of shares outstanding for BIO has been reduced compared to 1 year ago.
  • BIO has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BIO has an improved debt to assets ratio.
BIO Yearly Shares OutstandingBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
BIO Yearly Total Debt VS Total AssetsBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • BIO has an Altman-Z score of 3.17. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
  • BIO has a Altman-Z score of 3.17. This is in the better half of the industry: BIO outperforms 69.64% of its industry peers.
  • BIO has a debt to FCF ratio of 3.21. This is a good value and a sign of high solvency as BIO would need 3.21 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 3.21, BIO belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
  • BIO has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
  • BIO has a Debt to Equity ratio of 0.16. This is in the better half of the industry: BIO outperforms 60.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Altman-Z 3.17
ROIC/WACC0.19
WACC10.66%
BIO Yearly LT Debt VS Equity VS FCFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • BIO has a Current Ratio of 5.62. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 5.62, BIO belongs to the best of the industry, outperforming 83.93% of the companies in the same industry.
  • A Quick Ratio of 4.19 indicates that BIO has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.19, BIO is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.62
Quick Ratio 4.19
BIO Yearly Current Assets VS Current LiabilitesBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BIO Growth Analysis

3.1 Past

  • BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.78%.
  • Measured over the past years, BIO shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.19% on average per year.
  • BIO shows a small growth in Revenue. In the last year, the Revenue has grown by 0.65%.
  • The Revenue has been growing slightly by 0.29% on average over the past years.
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%

3.2 Future

  • Based on estimates for the next years, BIO will show a small growth in Earnings Per Share. The EPS will grow by 0.58% on average per year.
  • The Revenue is expected to grow by 2.54% on average over the next years.
EPS Next Y4.02%
EPS Next 2Y7.43%
EPS Next 3Y6.58%
EPS Next 5Y0.58%
Revenue Next Year2.04%
Revenue Next 2Y2.62%
Revenue Next 3Y2.62%
Revenue Next 5Y2.54%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BIO Yearly Revenue VS EstimatesBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B 2.5B
BIO Yearly EPS VS EstimatesBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10 15

More info and screens

Find the best growth stocksShow best growing peers

4

4. BIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 29.02, which means the current valuation is very expensive for BIO.
  • 67.86% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
  • The average S&P500 Price/Earnings ratio is at 27.42. BIO is around the same levels.
  • Based on the Price/Forward Earnings ratio of 27.89, the valuation of BIO can be described as expensive.
  • Based on the Price/Forward Earnings ratio, BIO is valued a bit cheaper than the industry average as 66.07% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (22.29), we can say BIO is valued slightly more expensively.
Industry RankSector Rank
PE 29.02
Fwd PE 27.89
BIO Price Earnings VS Forward Price EarningsBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 80.36% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.74
EV/EBITDA N/A
BIO Per share dataBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BIO does not grow enough to justify the current Price/Earnings ratio.
  • BIO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)7.21
PEG (5Y)N/A
EPS Next 2Y7.43%
EPS Next 3Y6.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIO Dividend Analysis

5.1 Amount

  • No dividends for BIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIO Fundamentals: All Metrics, Ratios and Statistics

BIO-RAD LABORATORIES-A

NYSE:BIO (4/24/2026, 8:23:14 PM)

After market: 287.84 0 (0%)

287.84

+6.42 (+2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners90.49%
Inst Owner Change1.36%
Ins Owners8.11%
Ins Owner Change0%
Market Cap7.77B
Revenue(TTM)2.58B
Net Income(TTM)759.90M
Analysts76
Price Target326.4 (13.4%)
Short Float %6.62%
Short Ratio3.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.88%
Min EPS beat(2)-7.97%
Max EPS beat(2)15.74%
EPS beat(4)3
Avg EPS beat(4)23.95%
Min EPS beat(4)-7.97%
Max EPS beat(4)49.07%
EPS beat(8)7
Avg EPS beat(8)28.31%
EPS beat(12)9
Avg EPS beat(12)18.55%
EPS beat(16)11
Avg EPS beat(16)17.09%
Revenue beat(2)0
Avg Revenue beat(2)-0.54%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)-0.35%
Revenue beat(4)2
Avg Revenue beat(4)1.22%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)0.02%
Revenue beat(12)3
Avg Revenue beat(12)-1.41%
Revenue beat(16)5
Avg Revenue beat(16)-1.09%
PT rev (1m)-4.48%
PT rev (3m)-9.86%
EPS NQ rev (1m)7.1%
EPS NQ rev (3m)-20.79%
EPS NY rev (1m)-0.52%
EPS NY rev (3m)0.67%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-1.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.34%
Valuation
Industry RankSector Rank
PE 29.02
Fwd PE 27.89
P/S 3.01
P/FCF 20.74
P/OCF 14.6
P/B 1.04
P/tB 1.16
EV/EBITDA N/A
EPS(TTM)9.92
EY3.45%
EPS(NY)10.32
Fwd EY3.59%
FCF(TTM)13.88
FCFY4.82%
OCF(TTM)19.72
OCFY6.85%
SpS95.71
BVpS276.16
TBVpS248.22
PEG (NY)7.21
PEG (5Y)N/A
Graham Number248.273 (-13.75%)
Profitability
Industry RankSector Rank
ROA 7.18%
ROE 10.2%
ROCE 2.65%
ROIC 2.02%
ROICexc 2.38%
ROICexgc 2.62%
OM 10.3%
PM (TTM) 29.42%
GM 52.01%
FCFM 14.5%
ROA(3y)-5.9%
ROA(5y)-4.13%
ROE(3y)-8.39%
ROE(5y)-6.36%
ROIC(3y)2.32%
ROIC(5y)2.47%
ROICexc(3y)2.76%
ROICexc(5y)2.85%
ROICexgc(3y)3.02%
ROICexgc(5y)3.08%
ROCE(3y)3.04%
ROCE(5y)3.23%
ROICexgc growth 3Y-9.86%
ROICexgc growth 5Y-2.45%
ROICexc growth 3Y-10.58%
ROICexc growth 5Y-3.39%
OM growth 3Y-15.99%
OM growth 5Y-9.05%
PM growth 3YN/A
PM growth 5Y-27.79%
GM growth 3Y-2.41%
GM growth 5Y-1.64%
F-Score5
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF 3.21
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 6.1%
Interest Coverage -5.71
Cash Conversion N/A
Profit Quality 49.3%
Current Ratio 5.62
Quick Ratio 4.19
Altman-Z 3.17
F-Score5
WACC10.66%
ROIC/WACC0.19
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)6.44%
Cap/Sales(5y)5.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3.78%
EPS 3Y-11.33%
EPS 5Y-1.19%
EPS Q2Q%-13.45%
EPS Next Y4.02%
EPS Next 2Y7.43%
EPS Next 3Y6.58%
EPS Next 5Y0.58%
Revenue 1Y (TTM)0.65%
Revenue growth 3Y-2.68%
Revenue growth 5Y0.29%
Sales Q2Q%3.85%
Revenue Next Year2.04%
Revenue Next 2Y2.62%
Revenue Next 3Y2.62%
Revenue Next 5Y2.54%
EBIT growth 1Y-12.48%
EBIT growth 3Y-18.24%
EBIT growth 5Y-8.78%
EBIT Next Year46.1%
EBIT Next 3Y19.79%
EBIT Next 5Y9.79%
FCF growth 1Y40.72%
FCF growth 3Y66.2%
FCF growth 5Y-4.69%
OCF growth 1Y16.92%
OCF growth 3Y39.89%
OCF growth 5Y-1.87%

BIO-RAD LABORATORIES-A / BIO Fundamental Analysis FAQ

What is the fundamental rating for BIO stock?

ChartMill assigns a fundamental rating of 5 / 10 to BIO.


Can you provide the valuation status for BIO-RAD LABORATORIES-A?

ChartMill assigns a valuation rating of 4 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Fairly Valued.


How profitable is BIO-RAD LABORATORIES-A (BIO) stock?

BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 6 / 10.


What is the valuation of BIO-RAD LABORATORIES-A based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 29.02 and the Price/Book (PB) ratio is 1.04.


Can you provide the expected EPS growth for BIO stock?

The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to grow by 4.02% in the next year.